Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of long-acting cabotegravir + rilpivirine versus Triumeq for maintenance of HIV-1 virologic suppression after switch
2016-001646-25Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabotegravir, rilpivirine long-acting and abacavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of participants with virologic failure at Week 48. Started Aug 2016; status: completed.
02
Drugs
cabotegravirrilpivirine long-actingabacavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2016-001646-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001646-25.